Altamira Therapeutics Business Summary

Altamira Therapeutics Ltd. (CYTOF) operates a "picks and shovels" biotechnology business model focused on the development and licensing of its proprietary xPhore™ peptide-based nanoparticle platform for extrahepatic RNA delivery. The company generates revenue through technology licensing fees, R&D service milestones, and the strategic out-licensing or divestment of its legacy clinical assets. Its primary business is segmented into RNA Delivery—comprising the OligoPhore™ (siRNA), SemaPhore™ (mRNA), and the newly branded CycloPhore™ (circular RNA) platforms—and a Legacy Portfolio featuring the Bentrio nasal spray and various Phase II/III inner ear and vertigo treatments. Positioned as a specialized alternative to traditional lipid nanoparticle (LNP) technologies, Altamira competes with firms like Biodexa Pharmaceuticals, Scinai Immunotherapeutics, and OptiNose, distinguishing itself by enabling systemic delivery to non-liver tissues such as solid tumors and inflamed joints. The leadership team is anchored by founder, Chairman, and CEO Dr. Thomas Meyer, who previously served as CEO of the medical device leader Disetronic Group. He is supported by Chief Operating Officer Dr. Covadonga Pañeda, an RNAi specialist with a pedigree from Sylentis S.A., and CFO Marcel Gremaud, a veteran of international pharmaceutical accounting. The company’s scientific foundation is heavily influenced by Chief Scientific Adviser Dr. Samuel A. Wickline, the founder of Trasir Therapeutics (acquired by Altamira) and a pioneer in nanomedicine from Washington University. The Board of Directors includes industry veterans such as Mats Blom, former CFO of NorthSea Therapeutics, and Dr. Alain Munoz, a former R&D executive at Sanofi and the Fournier Group, providing deep clinical and financial governance as the company executes its partial spin-off of the ATAG subsidiary.